Status | Study |
Not yet recruiting |
Study Name: ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2017-02-14 Interventions: Biological: ALXN1210 |
Recruiting |
Study Name: A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2017-02-01 Interventions: Drug: ACH-0144471 ACH-0144471 will be administered to all patients enrolled in the study. |
Recruiting |
Study Name: Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria Condition: Paroxysmal Hemoglobinuria, Nocturnal Date: 2016-11-01 Interventions: Drug: RO7112689 RO7112689 will |
Recruiting |
Study Name: ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2016-10-25 Interventions: Biological: ALXN1210 |
Active, not recruiting |
Study Name: A Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria Condition: Paroxysmal Nocturnal Hemoglobinuria PNH Date: 2015-11-11 Interventions: Biological: Study Drug- ALXN1210 |
Active, not recruiting |
Study Name: An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2015-11-02 Interventions: Biological: Study Drug - ALXN1210 |
Recruiting |
Study Name: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Condition: Paroxysmal Nocturnal Haemoglobinuria (PNH) Date: 2015-09-10 Interventions: Drug: Coversin Patients enrolled in this protocol will initially be treated with an ablating dose of Cov |
Recruiting |
Study Name: Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria Condition: Paroxysmal Nocturnal Hemoglobinuria PNH Date: 2015-08-07 Interventions: Biological: LFG316 LFG316 will be administered to all patients enrolled in the study |
Completed |
Study Name: Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study Condition: Paroxysmal Nocturnal Hemoglobinuria PNH Date: 2011-08-05 |
Active, not recruiting |
Study Name: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry Condition: Paroxysmal Nocturnal Hemoglobinuria Date: 2011-04-15 |